Is Corcept Therapeutics (CORT) overvalued or fairly valued?

MarketChacha shows Corcept Therapeutics's valuation in context — a trailing P/E of about 289.2, a forward P/E of about 28.9, a price-to-book of about 15.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Corcept Therapeutics's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.35×) from reported figures — education, not a rating.

What is Corcept Therapeutics's revenue?

Corcept Therapeutics reported revenue of $761.4M for FY2025, with net profit of $99.7M, per official filings.

What is the share price of Corcept Therapeutics (CORT)?

Corcept Therapeutics last traded at $92.53 (-3.3% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Corcept Therapeutics

CORT · NYSE · Healthcare · United States

$92.53-3.3%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:28 PM

Snapshot

TickerCORT

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees730

HeadquartersRedwood City, United States

Market cap$9.9B

P/E (TTM)289.2

P/B15.6

Volume475.75K

Websitewww.corcept.com

Filings tracked6

About Corcept Therapeutics

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Profile as reported by Yahoo Finance.

Who owns it

Insiders11.5%
Institutions75.6%
Public & other12.9%

490 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.11.32%
Ingalls & Snyder LLC7.09%
Renaissance Technologies, LLC5.29%
Vanguard Portfolio Management LLC4.49%
Vanguard Capital Management LLC3.80%
Parallel Advisors, LLC3.71%
State Street Corporation2.98%
FMR, LLC2.97%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Margin has compressed by about 8.9 points over the period — profitability is trending down.

Cash conversion1.35×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend22.0% → 13.1%

Margin has compressed by about 8.9 points over the period — profitability is trending down.

Return on equity15.4%

Latest ROE of 15.4% — capital is generating a healthy return.

Growth qualityrev 26% · PAT -3%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $274.3M · EPS 0.25

Est. earnings growth +58.3%

Next fiscal year

Rev $1.5B · EPS 3.21

Est. earnings growth +476.1%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$28.6652-wk range$95.79

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$9.9B

Day change

-3.3%

P/E (TTM)

289.2

Fwd P/E

28.9

P/B

15.6

Beta

0.46

Revenue (FY2025)

$761.4M

Net margin

13.1%

ROE

15.4%

Revenue CAGR (2y)

+25.6%

Profit CAGR (2y)

-3.1%

EPS (FY2025)

0.82

Net profit (FY2025)

$99.7M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about CORT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$761.4M	$99.7M	0.82	13.1%	15.4%
FY2024	$675.0M	$141.2M	1.23	20.9%	20.8%
FY2023	$482.4M	$106.1M	0.94	22.0%	20.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$164.9M	$-31.8M	-0.30	-19.3%
2025Q3	$207.6M	$19.7M	0.16	9.5%
2025Q2	$194.4M	$35.1M	0.29	18.1%
2025Q1	$157.2M	$20.5M	0.17	13.1%
2024Q3	$182.5M	$47.2M	0.41	25.9%
2024Q2	$163.8M	$35.5M	0.32	21.7%
2024Q1	$146.8M	$27.8M	0.25	18.9%
2023Q3	$123.6M	$31.4M	0.28	25.4%
2023Q2	$117.7M	$27.5M	0.25	23.4%
2023Q1	$105.7M	$15.9M	0.14	15.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Other events, Exhibits
SEC6/17/2026material
8-K — Other events
SEC6/3/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/28/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/30/2026
8-K — Other events, Exhibits
SEC3/25/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.